Contact Us
Drug Search Results
More Filters [+]

DNL-151

Alternative Names: dnl-151, dnl 151, dnl151
Latest Update: 2025-01-13
Latest Update Note: News Article

Product Description

DNL151 is an orally available, brain-penetrant inhibitor of the leucine-rich repeat kinase 2 (LRRK2). It started out as a backup to Denali’s lead LRRK2 inhibitor, DNL201; but it is now is its lead candidate after development of DNL201 was stopped in 2020. (Sourced from: https://www.alzforum.org/therapeutics/dnl151)

Mechanisms of Action: LRRK2 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biogen
Company Location: CAMBRIDGE MA 02142
Company CEO: Michel Vounatsos
Additonal Commercial Interests: Denali Therapeutics

Clinical Description

Map of Global Clinical Trials for DNL-151

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Parkinson's Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
LRRK2-PD

P2

Recruiting

Parkinson's Disease

2026-04-30

Recent News Events

Date

Type

Title

01/13/2025

News Article

 Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

12/05/2024

News Article

 Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson's Disease

05/09/2024

News Article

 US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson's Disease Treatments

01/08/2024

News Article

 Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

12/01/2023

PubMed

 Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.

03/01/2023

PubMed

 LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions